Australia's Cynata Therapeutics leaps as clinical trial progresses

Cynata Therapeutics

15/12/2025 04:11

** Shares of Cynata Therapeutics CYP.AX rise as much as 7.6% to A$0.285, their highest level since December 1

** Stock set for its strongest trading session in over a week, if current trends hold

** Stem cell and regenerative medicine maker says 65 patients have been enrolled in its Phase 2 clinical trial of CYP-001 in adults diagnosed with acute graft versus host disease (aGvHD)

** aGvHD is a life-threatening complication where donor’s immune cells attack recipient's tissues

** Co says CYP-001 is designed to modulate immune system and improve both response rates and survival outcomes in aGvHD

** Stock up 18.6% YTD, including session's moves

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))